Atrial fibrillation (AF) is the most common heart rhythm disorder. It affects >6 million Americans and is a major cause of stroke. Since AF is primarily an age-related disease, it is fast becoming an epidemic in an aging population. Unfortunately, current therapies for AF – both pharmacological and ablation-based – are sub-optimal in patients with persistent AF. Ablation – considered the ‘gold standard’ in AF treatment today, is moderately successful (70-75% efficacy) in patients with paroxysmal AF, but has suboptimal efficacy (&lt;50%) in persistent AF. This is thought to be in part because current treatments do not target fundamental, molecular mechanisms that cause AF.
|Effective start/end date||5/1/18 → 4/30/20|
- Cleveland Clinic Lerner College of Medicine of CWRU (982-SUB//3U54HL119810-05S1)
- National Heart, Lung, and Blood Institute (982-SUB//3U54HL119810-05S1)